English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

States, which have the primary legal role in regulating the prescribing and dispensing of prescription medications, have created Prescription Drug Monitoring Programs (PDMP) to try to reduce inappropriate prescribing, dispensing, and related harm. Research assessing whether these interventions are effective has produced inconclusive and contradictory results. Here we examine whether different data sources may have contributed to the varying results. Specifically, we: 1) identify the decisions inherent in creating such a dataset; 2) discuss the public data sources used by researchers in previous work; 3) develop and apply a detailed research protocol to create a novel PDMP law dataset; and 4) to illustrate potential consequences of data choice, apply various data sources to analyze the relationship between PDMP laws and prescribing and dispensing of opioids among disabled Medicare beneficiaries. We find that our dates differ from those in existing datasets, sometimes by many years. The regression analyses generated a twofold difference in point estimates, as well as different signed estimates, depending on the data used. We conclude that the lack of transparency about data assembly in existing datasets, differences among dates by source, and the regression results raise concerns for PDMP researchers and policymakers.

The Problem of Data Quality in Analyses of Opioid Regulation: The Case of Prescription Drug Monitoring Programs